Home LiteratureArticle Details
PMID: 20463105 Published · ppublish English Journal Article Review

Correlates of protection induced by vaccination.

Clinical and vaccine immunology : CVI ·Vol. 17 ·No. 7 ·2010-07-00 ·Pages 1055-65

Plotkin SA

Abstract

This paper attempts to summarize current knowledge about immune responses to vaccines that correlate with protection. Although the immune system is redundant, almost all current vaccines work through antibodies in serum or on mucosa that block infection or bacteremia/viremia and thus provide a correlate of protection. The functional characteristics of antibodies, as well as quantity, are important. Antibody may be highly correlated with protection or synergistic with other functions. Immune memory is a critical correlate: effector memory for short-incubation diseases and central memory for long-incubation diseases. Cellular immunity acts to kill or suppress intracellular pathogens and may also synergize with antibody. For some vaccines, we have no true correlates, but only useful surrogates, for an unknown protective response.

MeSH Terms
Antibodies Humans Immunity Immunity, Cellular Immunologic Memory Vaccines/immunology
Chemicals
Antibodies Vaccines
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Plotkin Stanley A
Vaxconsult, 4650 Wismer Road, Doylestown, PA 18902, USA. stanley.plotkin@vaxconsult.com
References (196)
196 references, click to expand
  1. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses.
    J Infect Dis. 1990 Dec;162(6):1291-7 PMID: 2172403
  2. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?
    Clin Infect Dis. 2008 Dec 1;47(11):1458-67 PMID: 18959494
  3. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
    Vaccine. 2008 Dec 9;26(52):6844-51 PMID: 18930097
  4. Development, acceptance, and use of immunologic correlates of protection in monitoring the effectiveness of combination vaccines.
    Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S274-7 PMID: 11709759
  5. Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages.
    Clin Exp Immunol. 1997 Dec;110(3):358-61 PMID: 9409636
  6. Duration of antiviral immunity after smallpox vaccination.
    Nat Med. 2003 Sep;9(9):1131-7 PMID: 12925846
  7. Rabies vaccines. WHO position paper.
    Wkly Epidemiol Rec. 2007 Dec 7;82(49-50):425-35 PMID: 18064757
  8. Developing an improved vaccine against tuberculosis.
    Expert Rev Vaccines. 2004 Jun;3(3):299-306 PMID: 15176946
  9. Determination of rubella virus-specific cell-mediated immunity using IFN gamma-ELISpot.
    J Med Virol. 2010 Feb;82(2):335-40 PMID: 20029797
  10. Cell mediated and antibody immune response to inactivated hepatitis A vaccine.
    Vaccine. 2005 Oct 25;23(44):5127-32 PMID: 16054733
  11. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.
    J Natl Cancer Inst. 2003 Aug 6;95(15):1128-37 PMID: 12902442
  12. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection.
    Pediatr Infect Dis J. 2002 Apr;21(4):337-42 PMID: 12075766
  13. Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations.
    J Infect Dis. 1997 Apr;175(4):749-55 PMID: 9086126
  14. Generating memory with vaccination.
    Eur J Immunol. 2009 Aug;39(8):2100-5 PMID: 19637203
  15. On immunity against infections and vaccines: credo 2004.
    Scand J Immunol. 2004 Jul-Aug;60(1-2):9-13 PMID: 15238068
  16. Inactivated rotavirus vaccines: a priority for accelerated vaccine development.
    Vaccine. 2008 Dec 9;26(52):6754-8 PMID: 18951937
  17. Immunologic correlates of protection induced by vaccination.
    Pediatr Infect Dis J. 2001 Jan;20(1):63-75 PMID: 11176570
  18. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic.
    Am J Hyg. 1962 Sep;76:173-95 PMID: 14469861
  19. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.
    Vaccine. 2007 May 10;25(19):3816-26 PMID: 17368878
  20. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
    Lancet. 2009 Jul 25;374(9686):301-14 PMID: 19586656
  21. Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics.
    Scand J Infect Dis. 1986;18(3):235-9 PMID: 3738434
  22. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
    Virology. 2004 Apr 10;321(2):205-16 PMID: 15051381
  23. A long-term prospective study of varicella vaccine in healthy children.
    Pediatrics. 1997 Nov;100(5):761-6 PMID: 9346974
  24. Systematic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease.
    J Virol. 1996 May;70(5):3075-83 PMID: 8627786
  25. Decline of measles antibody titers after immunization in human immunodeficiency virus-infected children.
    Pediatr Infect Dis J. 1995 Feb;14(2):149-51 PMID: 7746699
  26. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination.
    Infection. 2006 Aug;34(4):222-6 PMID: 16896582
  27. The immune response to BCG vaccination of newborns.
    Ann N Y Acad Sci. 2005 Dec;1062:69-78 PMID: 16461790
  28. Cell-mediated protection in influenza infection.
    Emerg Infect Dis. 2006 Jan;12(1):48-54 PMID: 16494717
  29. Virus-specific intestinal IFN-gamma producing T cell responses induced by human rotavirus infection and vaccines are correlated with protection against rotavirus diarrhea in gnotobiotic pigs.
    Vaccine. 2008 Jun 19;26(26):3322-31 PMID: 18456375
  30. Varicella in children with cancer: Seventy-seven cases.
    Pediatrics. 1975 Sep;56(3):388-97 PMID: 1088828
  31. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine.
    Ann Intern Med. 1988 Feb;108(2):185-9 PMID: 2963570
  32. Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies.
    Pediatr Res. 1973 Mar;7(3):103-10 PMID: 4120458
  33. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
    J Infect Dis. 2006 Jun 15;193(12):1658-65 PMID: 16703509
  34. Responses to measles immunization in children infected with human immunodeficiency virus.
    J Pediatr. 1994 Jul;125(1):72-4 PMID: 8021790
  35. Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections.
    J Infect Dis. 1994 Mar;169(3):504-11 PMID: 8158022
  36. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype.
    Vaccine. 2001 Feb 8;19(13-14):1727-31 PMID: 11166897
  37. What level of hepatitis B antibody is protective?
    J Infect Dis. 1999 Feb;179(2):489-92 PMID: 9878036
  38. A prospective study of serum antibody and protection against smallpox.
    Am J Trop Med Hyg. 1972 Mar;21(2):214-8 PMID: 5061278
  39. Generalized tetanus despite prior vaccination and a protective level of anti-tetanus antibodies.
    Am J Med Sci. 2010 Feb;339(2):200-1 PMID: 20019579
  40. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.
    J Infect Dis. 2008 Mar 15;197(6):825-35 PMID: 18419349
  41. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits.
    Infect Immun. 2006 Jan;74(1):394-8 PMID: 16368995
  42. Meningococcal surrogates of protection--serum bactericidal antibody activity.
    Vaccine. 2005 Mar 18;23(17-18):2222-7 PMID: 15755600
  43. Correlates of protection: novel generations of influenza vaccines.
    Vaccine. 2008 Sep 12;26 Suppl 4:D41-4 PMID: 19230158
  44. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
    Vaccine. 2009 Dec 30;27 Suppl 6:G72-81 PMID: 20006144
  45. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.
    Vaccine. 2004 Jan 2;22(3-4):422-30 PMID: 14670324
  46. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
    J Infect Dis. 2000 Mar;181(3):1133-7 PMID: 10720541
  47. Cell-mediated immune responsiveness to measles. Its occurrence as a result of naturally acquired or vaccine-induced infection and in infants of immune mothers.
    Am J Dis Child. 1981 Jan;135(1):48-51 PMID: 7457444
  48. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin.
    N Engl J Med. 1987 Oct 8;317(15):923-9 PMID: 2442610
  49. Measles antibody: reevaluation of protective titers.
    J Infect Dis. 1990 Nov;162(5):1036-42 PMID: 2230231
  50. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response.
    Pediatr Infect Dis J. 1992 Jan;11(1):19-23 PMID: 1312704
  51. Active immunity against rotavirus infection in mice is correlated with viral replication and titers of serum rotavirus IgA following vaccination.
    Virology. 1994 Nov 1;204(2):642-50 PMID: 7941332
  52. Immune correlates of protection against influenza in the human challenge model.
    Dev Biol (Basel). 2003;115:97-104 PMID: 15088780
  53. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo.
    J Virol. 2008 Jul;82(14):7009-21 PMID: 18480437
  54. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus.
    J Infect Dis. 1983 Oct;148(4):639-47 PMID: 6355309
  55. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.
    J Infect Dis. 2009 Oct 1;200(7):1068-77 PMID: 19712037
  56. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines.
    Biologicals. 1994 Dec;22(4):397-402 PMID: 7779368
  57. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine.
    J Immunol. 1969 Jun;102(6):1423-30 PMID: 4977607
  58. Correlating immunity with protection for HPV infection.
    Int J Infect Dis. 2007 Nov;11 Suppl 2:S10-6 PMID: 18162240
  59. Vaccination against the major infectious diseases.
    C R Acad Sci III. 1999 Nov;322(11):943-51 PMID: 10646088
  60. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model.
    Virology. 2008 Oct 25;380(2):296-303 PMID: 18774583
  61. Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia.
    Vaccine. 2008 Jul 4;26(29-30):3719-26 PMID: 18514974
  62. [Antitetanus antibodies. Assay before anatoxinotherapy in 64 tetanus patients].
    Nouv Presse Med. 1972 Dec 16;1(45):3049-50 PMID: 4675227
  63. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity.
    J Virol. 2010 Mar;84(5):2408-20 PMID: 20032181
  64. Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccines.
    N Engl J Med. 1969 Mar 20;280(12):628-33 PMID: 4179401
  65. Pathogenesis of rabies.
    Curr Top Microbiol Immunol. 2005;292:45-56 PMID: 15981467
  66. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Vaccine. 2008 Mar 20;26(13):1616-25 PMID: 18304706
  67. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity.
    J Exp Med. 2006 Feb 20;203(2):413-24 PMID: 16461338
  68. Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay.
    J Immunol Methods. 2006 Aug 31;315(1-2):144-52 PMID: 16959261
  69. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method.
    J Infect Dis. 2003 Aug 15;188(4):481-5 PMID: 12898433
  70. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004.
    Vaccine. 2005 Nov 1;23(45):5205-11 PMID: 16055233
  71. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults.
    Vaccine. 2009 Apr 21;27(18):2418-25 PMID: 19368783
  72. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.
    Clin Infect Dis. 2008 Jan 15;46(2):186-92 PMID: 18171249
  73. CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system.
    J Virol. 2006 Dec;80(24):12060-9 PMID: 17035323
  74. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration.
    J Infect Dis. 2000 Nov;182(5):1553-6 PMID: 11023481
  75. Passive immunization against hepatitis A.
    Vaccine. 1992;10 Suppl 1:S45-7 PMID: 1335658
  76. Primary vaccine failure after 1 dose of varicella vaccine in healthy children.
    J Infect Dis. 2008 Apr 1;197(7):944-9 PMID: 18419532
  77. Short-term immunoglobulin A B-cell memory resides in intestinal lymphoid tissues but not in bone marrow of gnotobiotic pigs inoculated with Wa human rotavirus.
    Immunology. 2001 Jun;103(2):188-98 PMID: 11412306
  78. Essential criteria for evaluation of pneumococcal conjugate vaccine candidates.
    Vaccine. 2009 Aug 21;27 Suppl 3:C15-8 PMID: 19683657
  79. The role of CD8+ T cells in immunity to tuberculosis infection.
    Trends Microbiol. 1993 Jun;1(3):77-8 PMID: 8143120
  80. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis.
    Vaccine. 2003 Sep 8;21(25-26):3542-9 PMID: 12922081
  81. Varicella vaccine revisited.
    Nat Med. 2000 Dec;6(12):1299-300 PMID: 11100089
  82. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
    Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11553-7 PMID: 8524802
  83. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.
    J Virol. 2006 Feb;80(4):1752-61 PMID: 16439532
  84. Vaccines: correlates of vaccine-induced immunity.
    Clin Infect Dis. 2008 Aug 1;47(3):401-9 PMID: 18558875
  85. Circulating antitoxin at the onset of diphtheria in 425 patients.
    J Immunol. 1946 Dec;54(4):325-47 PMID: 20278364
  86. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.
    Microb Pathog. 2007 Jan;42(1):11-21 PMID: 17107769
  87. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs).
    Vaccine. 2006 Feb 20;24(8):1170-9 PMID: 16191453
  88. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.
    PLoS Pathog. 2010 Feb 12;6(2):e1000790 PMID: 20168989
  89. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Vaccine. 2006 Aug 31;24 Suppl 3:S3/106-13 PMID: 16949996
  90. A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis.
    Pediatr Infect Dis J. 2000 Jul;19(7):589-91 PMID: 10917213
  91. IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein.
    Viral Immunol. 2007 Dec;20(4):571-84 PMID: 18158731
  92. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.
    Vaccine. 2009 Jan 22;27(4):597-605 PMID: 19022323
  93. Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys.
    J Infect Dis. 2004 Sep 1;190(5):998-1005 PMID: 15295708
  94. Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity.
    J Virol. 2008 Mar;82(6):3135-8 PMID: 18184712
  95. Mumps resurgences in the United States: A historical perspective on unexpected elements.
    Vaccine. 2009 Oct 19;27(44):6186-95 PMID: 19815120
  96. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines.
    Pediatrics. 1975 Sep;56(3):380-7 PMID: 1161394
  97. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals.
    J Virol. 2001 Dec;75(24):12182-7 PMID: 11711609
  98. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.
    Infect Immun. 1998 Jun;66(6):2453-9 PMID: 9596702
  99. The minimum protective level of antibodies in smallpox.
    Bull World Health Organ. 1975;52(3):307-11 PMID: 1084801
  100. Immunity and correlates of protection for rotavirus vaccines.
    Vaccine. 2006 Apr 5;24(15):2718-31 PMID: 16446014
  101. Relationship between structure and neutralizing activity of rabbit tetanus antibodies elicited by acellular and whole-cell pertussis DTP vaccines.
    Vaccine. 1998 Apr;16(7):672-7 PMID: 9562685
  102. Immunity to mumps in an institutional epidemic. Correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination-inhibiting antibodies.
    J Infect Dis. 1969 Jun;119(6):654-7 PMID: 4978535
  103. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection.
    J Virol. 2009 Oct;83(19):9652-62 PMID: 19625407
  104. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom.
    Pediatr Infect Dis J. 2010 May;29(5):401-5 PMID: 20010312
  105. Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.
    Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11581-8 PMID: 16037211
  106. Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype.
    Euro Surveill. 2008 Jun 26;13(26): PMID: 18761918
  107. Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus.
    N Engl J Med. 1971 Dec 9;285(24):1333-9 PMID: 4107718
  108. Measles virus-specific CD4 T-cell activity does not correlate with protection against lung infection or viral clearance.
    J Virol. 2007 Aug;81(16):8571-8 PMID: 17553890
  109. Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus.
    J Infect Dis. 2005 Aug 1;192(3):367-76 PMID: 15995949
  110. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies.
    J Infect Dis. 2010 Mar 15;201(6):923-35 PMID: 20158392
  111. Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
    J Infect Dis. 2008 May 1;197(9):1263-74 PMID: 18422438
  112. Six years' follow-up after hepatitis A vaccination.
    N Engl J Med. 1998 Apr 16;338(16):1160 PMID: 9547152
  113. Interstrain antigenic variability of mumps viruses.
    Clin Infect Dis. 2008 Jan 1;46(1):150-1 PMID: 18171235
  114. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.
    J Infect Dis. 2000 Mar;181(3):1010-3 PMID: 10720524
  115. The role of serum antibodies in the protection against rotavirus disease: an overview.
    Clin Infect Dis. 2002 May 15;34(10):1351-61 PMID: 11981731
  116. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice.
    Virology. 2004 Feb 20;319(2):262-73 PMID: 14980486
  117. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
    N Engl J Med. 1977 Sep 29;297(13):686-91 PMID: 408682
  118. Immunological correlates of protection from HIV infection and disease.
    Nat Immunol. 2006 Dec;7(12):1281-4 PMID: 17110946
  119. [Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland)].
    Rev Epidemiol Sante Publique. 1998 Mar;46(2):100-7 PMID: 9592852
  120. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination.
    Vaccine. 1996 Aug;14(11):1019-27 PMID: 8879096
  121. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.
    J Clin Microbiol. 1986 Jan;23(1):66-72 PMID: 3700610
  122. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada.
    Vaccine. 2009 Jun 8;27(28):3681-8 PMID: 19442421
  123. THE PROPHYLACTIC DOSE OF HOMOLOGOUS TETANUS ANTITOXIN.
    N Engl J Med. 1964 Jan 23;270:175-8 PMID: 14072072
  124. Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland.
    J Infect Dis. 1977 Aug;136 Suppl:S43-50 PMID: 408432
  125. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    N Engl J Med. 2005 Jun 2;352(22):2271-84 PMID: 15930418
  126. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine.
    N Engl J Med. 1989 Apr 6;320(14):892-7 PMID: 2538749
  127. Serum IgG mediates mucosal immunity against rotavirus infection.
    Proc Natl Acad Sci U S A. 2005 May 17;102(20):7268-73 PMID: 15883382
  128. The plaque-neutralization test as a measure of prior exposure to measles virus.
    J Infect Dis. 1987 Jan;155(1):146-9 PMID: 3794399
  129. The serological assessment of a tetanus toxoid field trial.
    Bull World Health Organ. 1971;45(6):773-85 PMID: 4947832
  130. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    J Infect Dis. 2003 Jul 15;188(2):327-38 PMID: 12854090
  131. In vitro correlate of immunity in a rabbit model of inhalational anthrax.
    Vaccine. 2001 Sep 14;19(32):4768-73 PMID: 11535328
  132. Sang Froid in a time of trouble: is a vaccine against HIV possible?
    J Int AIDS Soc. 2009 Feb 02;12:2 PMID: 19187552
  133. Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly.
    J Infect Dis. 2008 Mar 1;197(5):698-706 PMID: 18279050
  134. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.
    Infect Immun. 2007 Nov;75(11):5443-52 PMID: 17709410
  135. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children.
    Clin Vaccine Immunol. 2008 Jul;15(7):1042-53 PMID: 18448618
  136. Correlates of protective immunity in poxvirus infection: where does antibody stand?
    Immunol Cell Biol. 2008 Jan;86(1):80-6 PMID: 17923850
  137. Memory T-cell response to rotavirus detected with a gamma interferon enzyme-linked immunospot assay.
    J Virol. 2005 May;79(9):5684-94 PMID: 15827183
  138. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses.
    Epidemiol Infect. 1989 Apr;102(2):325-33 PMID: 2703026
  139. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign.
    Commun Dis Public Health. 2003 Apr;6(1):55-8 PMID: 12736974
  140. Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: relevance of antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and Th1-type cytokines as correlates of immunity.
    J Virol. 2009 Mar;83(6):2789-94 PMID: 19129445
  141. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal.
    Pediatr Infect Dis J. 1995 Mar;14(3):203-9 PMID: 7761185
  142. Recombinant DNA hepatitis B vaccination in teenagers: effect of a booster at 5 1/2 years.
    J Infect Dis. 1992 Oct;166(4):942 PMID: 1388197
  143. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Vaccine. 1998 Jan-Feb;16(2-3):298-304 PMID: 9607046
  144. Correlates of immune protection and the development of a human immunodeficiency virus vaccine.
    Immunity. 2007 Sep;27(3):366-9 PMID: 17892845
  145. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.
    Vaccine. 2003 Jul 4;21(23):3265-72 PMID: 12804857
  146. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak.
    J Infect Dis. 2008 Aug 15;198(4):508-15 PMID: 18558869
  147. Inactivated poliovirus vaccine: past and present experience.
    Vaccine. 1996 Jun;14(8):735-46 PMID: 8817819
  148. Measles and measles immunity in children infected with human immunodeficiency virus.
    JAMA. 1989 May 5;261(17):2512-6 PMID: 2704110
  149. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines.
    J Infect Dis. 1991 Jan;163(1):1-6 PMID: 1845806
  150. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.
    J Virol. 2008 Apr;82(7):3751-68 PMID: 18234801
  151. Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity.
    Viral Immunol. 2009 Dec;22(6):451-6 PMID: 19951182
  152. The immune response to pneumococcal proteins during experimental human carriage.
    J Exp Med. 2002 Feb 4;195(3):359-65 PMID: 11828011
  153. Specific prophylaxis of tetanus.
    J Am Med Assoc. 1959 Sep 26;171:417-27 PMID: 13819371
  154. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007.
    Vaccine. 2008 Aug 12;26(34):4299-303 PMID: 18582523
  155. The protective role of antibody responses during Mycobacterium tuberculosis infection.
    Clin Exp Immunol. 2009 Aug;157(2):235-43 PMID: 19604263
  156. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity.
    Clin Infect Dis. 1999 Aug;29(2):281-8 PMID: 10476727
  157. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children.
    Vaccine. 1999 Jun 4;17(20-21):2661-6 PMID: 10418916
  158. Correlates of immune protection from tuberculosis.
    Curr Mol Med. 2007 May;7(3):319-25 PMID: 17504116
  159. Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.
    Clin Vaccine Immunol. 2009 Mar;16(3):414-22 PMID: 19176692
  160. The role of secondary vaccine failures in measles outbreaks.
    Am J Public Health. 1989 Apr;79(4):475-8 PMID: 2929807
  161. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.
    J Infect Dis. 1983 Jun;147(6):1100 PMID: 6602191
  162. Imperfect memory and the development of Haemophilus influenzae type B disease.
    Pediatr Infect Dis J. 2001 Mar;20(3):235-9 PMID: 11303822
  163. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles.
    Nat Med. 2000 Jul;6(7):776-81 PMID: 10888926
  164. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
    Vaccine. 1998 Dec;16(20):1907-16 PMID: 9796042
  165. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview.
    J Hepatol. 1993;18 Suppl 2:S51-5 PMID: 8182275
  166. Rubella immunity. Defining the level of protective antibody.
    Am J Clin Pathol. 1996 Aug;106(2):170-4 PMID: 8712168
  167. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge.
    J Infect Dis. 1989 May;159(5):860-5 PMID: 2540247
  168. Immunity and immunological memory following smallpox vaccination.
    Immunol Rev. 2006 Jun;211:320-37 PMID: 16824139
  169. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
    Lancet. 2009 Dec 12;374(9706):1975-85 PMID: 19962185
  170. Role of virus strain in conventional and enhanced measles plaque neutralization test.
    J Virol Methods. 1981 Dec;3(5):251-60 PMID: 7334066
  171. CD4+ T cells control measles virus infection of the central nervous system.
    Immunology. 1992 Jun;76(2):185-91 PMID: 1353061
  172. Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin.
    J Infect Dis. 1987 Jul;156(1):56-63 PMID: 3110307
  173. Search for correlates of protective immunity conferred by anthrax vaccine.
    Infect Immun. 2001 May;69(5):2888-93 PMID: 11292703
  174. Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results.
    Arch Intern Med. 1991 Aug;151(8):1634-6 PMID: 1831343
  175. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants.
    J Hepatol. 1994 Aug;21(2):250-4 PMID: 7989718
  176. Lymphocyte responses to varicella zoster virus in the elderly.
    J Clin Immunol. 1987 Mar;7(2):174-8 PMID: 3033012
  177. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents.
    Pediatr Infect Dis J. 1995 Oct;14(10):874-9 PMID: 8584315
  178. Correlates of immunity for pneumococcal conjugate vaccines.
    Vaccine. 2003 May 16;21(17-18):2190-6 PMID: 12706710
  179. The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men.
    Ann Intern Med. 1982 Sep;97(3):362-6 PMID: 6810736
  180. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge.
    Nat Immunol. 2007 Apr;8(4):369-77 PMID: 17351619
  181. T cell responses are better correlates of vaccine protection in the elderly.
    J Immunol. 2006 May 15;176(10):6333-9 PMID: 16670345
  182. Response to hepatitis B immunization in children with hemophilia: relationship to infection with human immunodeficiency virus type 1.
    J Pediatr. 1990 Sep;117(3):427-30 PMID: 2391599
  183. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity.
    Nat Med. 2010 Feb;16(2):224-7 PMID: 20081864
  184. Neonatal tetanus despite immunization and protective antitoxin antibody.
    J Infect Dis. 1995 Apr;171(4):1076-7 PMID: 7706800
  185. Pathogenesis of dengue: challenges to molecular biology.
    Science. 1988 Jan 29;239(4839):476-81 PMID: 3277268
  186. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice.
    J Clin Invest. 2009 Jul;119(7):1899-909 PMID: 19509469
  187. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.
    Hepatology. 1981 Sep-Oct;1(5):377-85 PMID: 7030902
  188. Progressive immunodeficiency due to infection with human immunodeficiency virus does not lead to waning immunity to measles in a cohort of homosexual men.
    Clin Infect Dis. 1994 Apr;18(4):636-8 PMID: 8038324
  189. Long-term presence of memory B-cells specific for different vaccine components.
    Vaccine. 2009 Dec 10;28(1):179-86 PMID: 19799844
  190. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
    Vaccine. 1998 Dec;16(20):1901-6 PMID: 9796041
  191. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.
    J Virol. 2006 Jul;80(13):6333-8 PMID: 16775321
  192. Research on dengue during World War II.
    Am J Trop Med Hyg. 1952 Jan;1(1):30-50 PMID: 14903434
  193. Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys.
    J Virol. 2003 Apr;77(7):4396-400 PMID: 12634396
  194. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine.
    Appl Microbiol. 1973 Apr;25(4):539-44 PMID: 4633476
  195. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
    N Engl J Med. 2007 May 10;356(19):1915-27 PMID: 17494925
  196. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.
    J Virol. 1995 Jun;69(6):3959-63 PMID: 7745754
Article Info
Journal
Clinical and vaccine immunology : CVI
Abbr.
Clin Vaccine Immunol
ISSN
1556-679X
DOI
10.1128/CVI.00131-10
Email
stanley.plotkin@vaxconsult.com
Published
2010-07-00
Epub
2010-00-12
Pages
1055-65
Language
English
Region
United States
NLM ID
101252125
PMCID
PMC2897268
Subset
IM
External Links
PubMed source DOI: 10.1128/CVI.00131-10 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2